LOS ANGELES, Feb 28 (Reuters) - Pfizer Inc, which last year cut more than 15 percent of its drug development programs following a merger with Wyeth, said on Monday it has 25 compounds in late-stage development.
The company, the world's largest drugmaker, said another nine drugs are under review by regulators.
Pfizer also said it plans to update the status of its pipeline four times a year.
Pharmaceutical companies have come under increasing pressure to beef up their drug development pipelines as a growing number of top-selling drugs approach their patent expirations.
Pfizer's cholesterol-lowering drug Lipitor, which had 2011 sales of nearly $11 billion, could face its first generic competition late this year.
(Reporting by Deena Beasley; Editing by Richard Chang) Keywords: PFIZER PIPELINE/ (deena.beasley@thomsonreuters.com; + 1 213-955-6746) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The company, the world's largest drugmaker, said another nine drugs are under review by regulators.
Pfizer also said it plans to update the status of its pipeline four times a year.
Pharmaceutical companies have come under increasing pressure to beef up their drug development pipelines as a growing number of top-selling drugs approach their patent expirations.
Pfizer's cholesterol-lowering drug Lipitor, which had 2011 sales of nearly $11 billion, could face its first generic competition late this year.
(Reporting by Deena Beasley; Editing by Richard Chang) Keywords: PFIZER PIPELINE/ (deena.beasley@thomsonreuters.com; + 1 213-955-6746) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.